Advantage Investment Management’s Alterity Therapeutics ATHE Stock Holding History

Advantage Investment Management’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1K	Hold	107	–	–	﹤0.01%	880
2019 Q2	$1K	Sell	107 -5	-4%	-$80	﹤0.01%	894
2019 Q1	$2K	Hold	112	–	–	﹤0.01%	848
2018 Q4	$1K	Hold	112	–	–	﹤0.01%	943
2018 Q3	$2K	Hold	112	–	–	﹤0.01%	932
2018 Q2	$2K	Hold	112	–	–	﹤0.01%	854
2018 Q1	$2K	Hold	112	–	–	﹤0.01%	895
2017 Q4	$3K	Hold	112	–	–	﹤0.01%	872
2017 Q3	$3K	Hold	112	–	–	﹤0.01%	882
2017 Q2	$3K	Hold	112	–	–	﹤0.01%	899
2017 Q1	$3K	Hold	112	–	–	﹤0.01%	855
2016 Q4	$2K	Sell	112 -33	-23%	-$882	﹤0.01%	838
2016 Q3	$7K	Hold	145	–	–	﹤0.01%	678
2016 Q2	$7K	Hold	145	–	–	﹤0.01%	650
2016 Q1	$4K	Hold	145	–	–	﹤0.01%	694
2015 Q4	$6K	Hold	145	–	–	﹤0.01%	650
2015 Q3	$8K	Hold	145	–	–	﹤0.01%	575
2015 Q2	$10K	Hold	145	–	–	﹤0.01%	592
2015 Q1	$10K	Hold	145	–	–	0.01%	579
2014 Q4	$14K	Buy	+145	New	+$15.7K	0.01%	465

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Advantage Investment Management's ATHE Position: Q3 2019 in Review

Advantage Investment Management held its Alterity Therapeutics (ATHE) position steady in Q3 2019 at 107 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Advantage Investment Management first reported a position in ATHE in Q4 2014 and has held it in 20 quarters since. The position peaked at $14K in Q4 2014. 9 funds tracked by Wall St. Rank hold ATHE as of Q3 2019.

Advantage Investment Management held 107 shares of Alterity Therapeutics worth $1K as of Q3 2019.
Advantage Investment Management left its Alterity Therapeutics share count unchanged in Q3 2019.
Alterity Therapeutics made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #880 holding.
Advantage Investment Management first reported a position in Alterity Therapeutics in Q4 2014 and has held it in 20 quarters since.
Advantage Investment Management's Alterity Therapeutics position peaked at $14K in Q4 2014.
9 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.